TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

by Caihua Xu, MD, Dapeng Li, MD, Weiming Duan, MD, Min Tao, PhD
Published 2020-06-01